Company news
PolyPid Ltd. news in 2024
PolyPid Ltd.'s news releases, calls and decks from 2024, newest first.
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
December 23, 2024
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
December 10, 2024
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
November 28, 2024
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
November 6, 2024
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
October 29, 2024
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
October 20, 2024
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
September 30, 2024
PolyPid to Participate in Three Upcoming Fall Investor Conferences
September 2, 2024
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
August 1, 2024
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
July 30, 2024
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
June 17, 2024
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
June 9, 2024
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 7, 2024
PolyPid to Participate in Citizens JMP Life Sciences Conference
April 30, 2024
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
April 29, 2024
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
April 23, 2024
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
February 27, 2024
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 13, 2024
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
February 11, 2024
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
January 30, 2024
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
January 3, 2024